Alere Inc. Secures Important Permissions for Previously Announced Transaction Involving BBI Diagnostics Group plc

Alere Inc. Secures Important Permissions for Previously Announced Transaction
                     Involving BBI Diagnostics Group plc

PR Newswire

WALTHAM, Mass., June 5, 2014

WALTHAM, Mass., June 5, 2014 /PRNewswire/ --Alere Inc. (NYSE: ALR) (the
"Company") announced that it has received the requisite consents for its
consent solicitations commenced on May 21, 2014 relating to certain waivers
and amendments under the respective indentures (together, the "Notes
Modifications") governing its 7.25% Senior Notes due 2018 (the "7.25% Notes"),
its 8.625% Senior Subordinated Notes due 2018 (the "8.625% Notes") and its
6.5% Senior Subordinated Notes due 2020 (the "6.5% Notes," and, together with
the 7.25% Notes and the 8.625% Notes, the "Notes") relating to the BBI
Transaction (as defined below). The Company also announced that it and certain
of its subsidiaries have entered into a Fifth Amendment (the "Credit Agreement
Amendment") to its secured Credit Agreement with certain lenders, General
Electric Capital Corporation as collateral agent and administrative agent, and
certain other agents and arrangers, as previously amended, to obtain similar
permissions. The Notes Modifications (once operative as described below) and
the Credit Agreement Amendment will permit the Company and its subsidiaries to
consummate the BBI Transaction, among other matters.

The "BBI Transaction" is the previously announced proposed initial public
offering by the Company's subsidiary BBI Diagnostics Group plc ("BBI") of its
ordinary shares (the "BBI Securities") in the United Kingdom and the sale of
such shares in certain other jurisdictions, together with certain related
transactions anticipated to be conducted by the Company and its subsidiaries
in connection therewith as previously announced by the Company.

IPREO LLC, the information and tabulation agent for the consent solicitation,
has advised the Company that as of the expiration of the consent solicitations
at 5:00 p.m., New York City time, on June 4, 2014, the Company had received
consents that had not been withdrawn in respect of a majority in aggregate
principal amount of each of the 7.25% Notes, the 8.625% Notes and the 6.5%
Notes outstanding as of the record date. Following the receipt of the
requisite consents from holders of the Notes, the Company entered into
supplemental indentures implementing the Notes Modifications, substantially as
described in the consent solicitations documents. The Notes Modifications
will become operative only upon the Company's payment of the consent fee as
described in the consent solicitation documents. The Company expects to pay
the consent fee to the relevant holders in connection with the consummation of
the BBI Transaction, but it is not obligated to make the Notes Modifications
operative by paying the consent fee or to consummate the BBI Transaction. The
Company is required to pay certain amendment fees to the consenting lenders
under the Credit Agreement Amendment, although payment of such fees is not a
condition to the effectiveness of the Credit Agreement Amendment.

IMPORTANT NOTICES REGARDING THE BBI TRANSACTION

This press release does not constitute an offer to buy or sell or the
solicitation of an offer to buy or sell any of the securities described or
otherwise referred to in this press release (including, without limitation,
the BBI Securities referred to herein) or any of the documents referenced
herein. There shall not be any sale of the securities described or otherwise
referred to herein (including, without limitation, the BBI Securities) in any
jurisdiction in which the offer, solicitation or sale would be unlawful prior
to registration, exemption from registration or qualification under the
securities laws of any such jurisdiction. The offer and sale of the securities
described or otherwise referred to herein (including, without limitation, the
BBI Securities) in the United States may only be made pursuant to registration
under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and
registration or qualification under the securities laws of other applicable
jurisdictions or exemptions from such laws. The Company has no intention to
register the offer and sale of any such securities under the Securities Act or
other securities laws or to conduct a public offering of such securities in
the United States.

This press release does not constitute an offer of securities to the public in
the United Kingdom. Consequently, this press release is directed only at (i)
persons who are outside the United Kingdom or (ii) persons who have
professional experience in matters relating to investments falling within
Article 19(1) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (the "Order"), (iii) high net worth entities falling
within Article 49(2) of the Order and (iv) other persons to whom it may
lawfully be communicated (all such persons being referred to as "relevant
persons"). Any investment activity to which this communication relates will
only be available to, and will only be engaged in with, relevant persons. Any
person who is not a relevant person should not act or rely on this press
release or any of its contents.

Copies of this announcement are not being made and may not be distributed or
sent into Canada, Australia or Japan.

SOURCE Alere Inc.

Website: http://www.alere.com
Contact: Doug Guarino, Director of Corporate Relations, (781) 647-3900
 
Press spacebar to pause and continue. Press esc to stop.